Emerging role of eosinophils in immune-related adverse events related to therapy with immune checkpoint inhibitors

Pol Arch Intern Med. 2021 Oct 27;131(10):16092. doi: 10.20452/pamw.16092. Epub 2021 Oct 27.

Authors

Manuel Ramos-Casals¹, Alejandra Flores-Chavez^{2

3}, Pilar Brito-Zerón⁴

Affiliations

¹ Department of Autoimmune Diseases, ICMiD, Hospital Clinic, Barcelona, Spain. mramos@clinic.cat
² Department of Autoimmune Diseases, ICMiD, Hospital Clinic, Barcelona, Spain
³ Consejo Nacional de Ciencia y Tecnología (CONACYT), México DF, México
⁴ Autoimmune Diseases Unit, Department of Medicine, Hospital CIMA-Sanitas, Barcelona, Spain

PMID: 34704705
DOI: 10.20452/pamw.16092

No abstract available

Publication types

Editorial
Comment

MeSH terms

Causality
Eosinophils*
Humans
Immune Checkpoint Inhibitors*
Immunotherapy
Leukocyte Count

Substances

Immune Checkpoint Inhibitors